PROSTATE ADENOCARCINOMA

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This phase 3 trial tests whether treatment for high-risk prostate cancer can be personalized based on a patient's genetic risk score. For those with a low genetic risk, a shorter course of hormone therapy plus radiation may be as effective as the standard 24-month treatment, with…

This phase II trial tests whether adding the hormone-blocking drug relugolix to standard radiation therapy can slow cancer growth in men with prostate cancer that has spread to a few other spots in the body (oligometastatic). About 194 participants will receive either radiation a…

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This phase III trial tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to nearby lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus …

This phase III trial uses a genetic test (Decipher score) to personalize treatment for men with unfavorable intermediate-risk prostate cancer. For those with a high genetic risk, the study tests adding darolutamide to standard hormone therapy and radiation. For those with low gen…

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer wil…

This phase II trial tests whether green tea catechins (GTC) can prevent low-risk prostate cancer from progressing in men on active surveillance. 360 participants will receive either GTC or a placebo daily. The study measures changes in a tumor growth marker (Ki-67) in biopsy samp…

This phase 2 trial is testing whether adding the drug sunitinib to standard hormone therapy can shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with localized but aggressive prostate cancer will receive sunitinib pills plus a hormone block…

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for sur…

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…

This phase 2 trial tests whether a personalized walking program can slow the progression of localized prostate cancer in men who are on active surveillance (monitoring instead of immediate treatment). The 36 participants will exercise up to 5 times per week for 225-300 minutes to…

This phase 2 trial tests whether white button mushroom extract can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and not yet treated. About 133 men will take the supplement or be observed. The goal is to see if the mushroom affects …

This phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …

This Phase 3 trial compares two hormone therapies (GnRH antagonist vs GnRH agonist) given alongside radiation for men with very high-risk localized or locally advanced prostate cancer. The main goal is to see which combination better delays cancer progression. The study enrolled …

This phase III trial compares two types of image-guided radiation for prostate cancer: CT-guided and MRI-guided stereotactic body radiotherapy (SBRT). About 179 men with localized prostate cancer will receive the same radiation dose, but one group's treatment is guided by CT scan…

This early-phase trial tests whether giving higher doses of radiation to the prostate in fewer sessions (while also treating pelvic lymph nodes) is safe for men with intermediate- to high-risk prostate cancer. The study enrolls 18 adults and uses proton beam therapy delivered fou…

This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can cont…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery…

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects th…

This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naïve metastatic prostate cancer. The goal is to see how long patients can stay on treatment and how well it controls the cancer. All three drugs work by lowering or blocking…

This phase 2 trial tests whether combining golimumab (an anti-inflammatory drug) with apalutamide (a hormone blocker) can help men with castration-resistant prostate cancer that has spread. The study enrolled 8 participants and measures PSA reduction and tumor shrinkage. The goal…

This study tests a type of radiation called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose to the tumor while sparing nearby healthy tissue. The goal is to control…

This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage pros…

This phase 2 trial is testing a combination of radium-223 (a radioactive drug that targets bone tumors), hormone therapy, and precise radiation for men with prostate cancer that has spread to a few other places in the body. The goal is to see if this triple approach can delay can…

This study tests whether a daily dose of green tea catechins (a natural compound) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are not receiving immediate treatment. Over 24 months, 115 men will receive either the green tea extract or a plac…

This study tests whether taking apalutamide for 6 months before prostate removal surgery can reduce signs of aggressive cancer that often lead to radiation therapy afterward. It involves 45 men with intermediate-risk prostate cancer. The goal is to see if this approach can make s…

This study tests whether using advanced MRI scans to guide radiation therapy can reduce side effects for men with localized prostate cancer. Depending on their MRI results, patients receive either a short course of radiation or a longer treatment with a targeted boost to visible …

This early-phase study tests whether a bicalutamide implant placed directly into the prostate can replace standard hormone shots for men with localized prostate cancer receiving radiation. About 20 participants with intermediate- or high-risk cancer will receive the implant plus …

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI, can better control cancer while reducing side effects. About 164 men with prostate cancer will receive either the standard radiation or the standard plu…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 men will receive either hormone therapy or hormone therapy plus abirate…

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate c…

This study compares three different radiotherapy techniques for prostate cancer: standard treatment, a shorter course (SBRT), and a booster approach. Over 500 participants are being followed to see which method best controls cancer while minimizing side effects and preserving qua…

This phase 2 trial is testing whether surgery and radiation can help men whose prostate cancer has come back and spread to a few spots in the body. About 20 participants will receive either surgery to remove the spread tumors or targeted radiation, or both. The main goal is to se…

This phase 2 trial tests whether adding enzalutamide to standard hormone therapy and chemotherapy can better control metastatic prostate cancer that still responds to hormones. About 40 men with advanced disease will receive all three drugs. The main goal is to see how many achie…

This phase 3 study tests whether combining two drugs—cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy)—works better than standard hormone therapy for men with metastatic castration-resistant prostate cancer that has progressed after one prior hormone treatment…

This early-phase trial tests whether combining two types of targeted radiation is safe for men whose prostate cancer has returned after prostate removal surgery. The treatment uses a special scan to find cancer cells, then delivers high-energy rays and a radioactive drug directly…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer in Asian men. One method, SBRT, delivers high-dose radiation in fewer sessions, while the other, IMRT, uses more standard daily doses. The main goal is to see which approach better pr…

This study tested whether a shorter, more intense radiation schedule (5 sessions) works as well as the standard longer schedule (26 sessions) for men with prostate cancer. The goal was to see if the shorter treatment could control the cancer just as well, based on PSA levels afte…

This study is testing whether a special MRI contrast called hyperpolarized pyruvate can help doctors see prostate tumors more clearly than standard MRI. About 130 men with prostate cancer will receive the contrast before imaging. The goal is to improve cancer detection and diagno…

This study tests a new 3D MRI technique to see if it can detect prostate cancer as well as or better than standard MRI, without needing an endorectal coil. It involves 33 men with untreated prostate cancer who are scheduled for surgery. The goal is to improve imaging comfort and …

This study tests whether a special PET scan using a tracer called 68Ga-PSMA-11 can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer at different stages will get the scan. The goal is to see if the scan changes how doctors plan treatment, s…

This study tests a new software that combines MRI images with real-time ultrasound to guide prostate biopsies. The goal is to help doctors more accurately detect and locate aggressive prostate cancer early. About 100 men scheduled for a standard prostate biopsy will take part. Th…

This study tests whether adding furosemide, a diuretic that increases urine flow, to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels have risen after prostate removal. The goal is to see if this …

This study is testing whether a type of PET scan called PSMA PET is more accurate than standard scans (like CT or bone scans) for monitoring prostate cancer. About 58 men with progressive prostate cancer will receive an injection of a radioactive tracer and then undergo PET/CT im…

This study tests a procedure called prostatic artery embolization (PAE) in 17 men with low-risk prostate cancer who also have trouble urinating. The goal is to see if PAE can reduce urinary symptoms before they start radiation therapy. Participants will have their symptoms and pr…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer: proton therapy (PBT) and intensity-modulated radiation therapy (IMRT). Both are thought to be equally effective at treating the cancer, but it's unclear which causes fewer side effec…

This study tests a new way to give radiotherapy for men with intermediate-risk prostate cancer. The goal is to lower the dose to healthy parts of the prostate while boosting the dose to the tumor, using a special MRI-guided machine (MR-linac). Twenty men will take part to see if …

This study follows 120 men who had robot-assisted surgery for prostate cancer to see how they are doing 10 years later. Researchers will check if the cancer has come back, how common incontinence and erectile dysfunction are, and how satisfied patients feel. The goal is to unders…

This study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…

This study explores whether a genetic test can identify prostate cancer patients at higher risk for urinary side effects from radiation therapy. Researchers will track side effects in 208 men with early-stage prostate cancer who receive stereotactic radiation. The goal is to see …

This study looks at whether standard hormone therapy (apalutamide, darolutamide, or enzalutamide) can increase the visibility of prostate cancer cells on PSMA PET/CT scans. About 9 men with recurrent prostate cancer will take the hormone pill for a few weeks and then get a scan. …

This study tests a method called KIM that tracks the prostate's position during radiation using implanted gold markers. If the prostate moves more than 3mm, the radiation beam stops and is repositioned. The goal is to see if this technique is feasible in 100 men receiving radiati…

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …

This study looks at how prostate cancer changes after radiation treatment using special MRI scans. Researchers want to see if these scans can help doctors manage treatment better and sooner. About 120 men with prostate cancer who are getting radiation will take part.

This study looks at whether a protein in the blood called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels in 118 men before, during, and after treatment. The goal is to see if changes in CgA are …

This study was designed to explore how the drug ruxolitinib affects immune cells inside prostate tumors. Researchers planned to give the drug to men with prostate cancer for 28 days before their scheduled surgery, then analyze tumor and blood samples. However, the study was withd…

This study was designed to observe changes in certain immune system proteins (chemokines) in the blood and urine of men with prostate cancer over time. Researchers planned to collect samples from patients starting new treatments, but the study was withdrawn before any participant…